ArticleJACC. Case reports2026
Secondary Cardiac Lymphoma Causing High-Grade Heart Block: Pacemaker Considerations in an Unpredictable Clinical Course.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac lymphoma can cause rapidly progressive high-grade atrioventricular block by infiltrating the conduction system. Because conduction disease may improve with lymphoma-directed therapy, pacemaker decisions are complex. CASE SUMMARY: A 44-year-old man with lymphoma developed extensive secondary cardiac involvement and progressive conduction system disease. Given the possibility of reversibility with immunotherapy, multidisciplinary discussions and shared decision-making were used to determine whether pacemaker implantation was warranted and to select the most appropriate device. An active-fixation leadless pacemaker was ultimately implanted. DISCUSSION: This case highlights the uncertainty regarding pacemaker management in cardiac lymphoma. Decisions should be individualized based on expected treatment response, infection risk, and patient preferences. TAKE-HOME MESSAGES: Cardiac lymphoma may present with rapidly progressive conduction disease, and the degree of reversibility following lymphoma-directed therapy can be difficult to predict. Decisions regarding pacemaker implantation should be individualized and informed by the expected treatment response, infectious and procedural risks, and patient preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.